The initiation and maintenance of chronic interstitial pulmonary inflammation is often due to dynamic interactions between an inciting agents, and structural cells of the lung. Clinically, the therapeutic modalities that are available to treat these diseases are limited, which likely reflects an insufficient understanding of the pathophysiologic mechanisms that mediate-these disorders. Independent of the various etiologies, many chronic interstitial lung diseases appear to possess a number of similar pathologic responses, including an initial elicitation of various leukocyte populations to the lung, subsequent fibroblast activation and proliferation, and deposition of extracellular matrix. Understanding the cellular and molecular mechanisms which are responsible for fibroblast activation during the initiation, maintenance, and resolution of interstitial lung inflammation are the broad, long-term objectives of this application. The working hypothesis of this proposal is the following: an exacerbation of fibroblast activation and tissue fibrosis during the evolution of chronic. interstitial lung inflammation is dependent upon the expression of a specific disease phenotype characterized by the predominance of Th2-type cytokines. This hypothesis will be addressed by focusing on fibrotic mechanisms which occur during the development of a Thl (minimally fibrotic) versus a Th2 type (fibrotic) immune response in the lung. Specific areas of cytokine biology that w:Ill be assessed include: l)- the contribution of Th2-like cytokines, especially interleukin-4, interleukin-5, and interleukin-10, to fibroblast activation leading to pulmonary fibrosis; 2) the role of Thl like cytokines, especially interleukin-12 and gamma interferon, in altering fibroblast activation during pulmonary fibrosis; 3) a mechanistic analysis of the contribution of cytokines to interstitial inflammation via adenovirus/cytokine cDNA transfection studies; 4) the contribution of activated fibroblasts isolated from either Th1 or Th2 lung lesions to progressive lung inflammation; and 5) the expression and regulation of Th2-like cytokine profiles in human patients and correlations with interstitial lung fibrosis. Animal models of chronic interstitial lung inflammation will be utilized to assess the contribution of Th1 like and Th2 like cytokines during pulmonary fibroblast activation and lung collagen deposition. A number of techniques will be employed in this application, including the use of Northern blot, reverse transcription-polymerase chain reaction (RT-PCR), mRNA stability, and in situ hybridization analyses for studying the regulation of gene expression; the use of immunohistochemistry for antigen localization and ELISAs for the quantitation of cytokines and endogenous mediators of cytokine activity; gene transfection strategies using adenovirus containing either a murine IL-4, IL-5, IL-10, gammaIFN, or IL-12 cDNA cassette and bioassays for assessing functional activities of specific mediators.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL056402-05
Application #
6410567
Study Section
Project Start
2000-12-15
Project End
2001-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
2001
Total Cost
$208,827
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Schmidt, S L; Nambiar, A M; Tayob, N et al. (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:176-83
Trujillo, Glenda; Meneghin, Alessia; Flaherty, Kevin R et al. (2010) TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2:57ra82
Fell, Charlene D; Martinez, Fernando J; Liu, Lyrica X et al. (2010) Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181:832-7
Huang, Steven K; White, Eric S; Wettlaufer, Scott H et al. (2009) Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J 23:4317-26
Fell, Charlene D; Liu, Lyrica Xiaohong; Motika, Caroline et al. (2009) The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179:402-7
White, Kimberly E; Ding, Qiang; Moore, Bethany B et al. (2008) Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol 180:637-46
Huang, Steven K; Peters-Golden, Marc (2008) Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest 133:1442-50
Han, M K; Murray, S; Fell, C D et al. (2008) Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 31:1183-8
Muro, Andres F; Moretti, Federico A; Moore, Bethany B et al. (2008) An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177:638-45
Huang, Steven K; Wettlaufer, Scott H; Hogaboam, Cory M et al. (2008) Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med 177:66-74

Showing the most recent 10 out of 96 publications